293 related articles for article (PubMed ID: 37460853)
1. Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim.
Lombardo-Del Toro P; Bragado-Trigo I; Arroyo P; Tena-Cucala R; Bau L; Matas E; Muñoz-Vendrell A; Simó M; Pons-Escoda A; Martínez-Yélamos A; Martínez-Yélamos S; Romero-Pinel L
J Neurol; 2023 Nov; 270(11):5196-5200. PubMed ID: 37460853
[No Abstract] [Full Text] [Related]
2. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
Maillart E; Louapre C; Lubetzki C; Papeix C
Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
[TBL] [Abstract][Full Text] [Related]
3. Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
Boudot de la Motte M; Louapre C; Bertrand A; Reach P; Lubetzki C; Papeix C; Maillart E
Mult Scler; 2017 Apr; 23(4):614-616. PubMed ID: 28273764
[TBL] [Abstract][Full Text] [Related]
4. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
[TBL] [Abstract][Full Text] [Related]
5. Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
Sriwastava S; Chaudhary D; Srivastava S; Beard K; Bai X; Wen S; Khalid SH; Lisak RP
J Neurol; 2022 Mar; 269(3):1678-1687. PubMed ID: 34800168
[TBL] [Abstract][Full Text] [Related]
6. Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.
Barritt AW; Das E; Morley N; Seymour M; Saha R; Vera J; Vundavalli S; Dizdarevic S; Nicholas R; Berger JR; Fisniku LK
Mult Scler; 2023 Feb; 29(2):301-306. PubMed ID: 36451581
[TBL] [Abstract][Full Text] [Related]
7. Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report.
Mickeviciene D; Baltusiene A; Afanasjeva B; Afanasjevas D; Gleizniene R; Rastenyte D; Berger JR
BMC Neurol; 2022 Aug; 22(1):306. PubMed ID: 35986243
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Findings Suggestive of Paraclinical Progressive Multifocal Leukoencephalopathy and Lung Cancer-Derived Brain Metastases in an MS Patient Treated With Fingolimod.
Maass F; von Gottberg P; Franz J; Stadelmann C; Bähr M; Weber MS
Front Neurol; 2021; 12():561158. PubMed ID: 33613428
[TBL] [Abstract][Full Text] [Related]
9. Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome after Discontinuation of Fingolimod.
Piñar Morales R; Carrasco Garcia M; Gutierrez-Rojas L; Barrero Hernández FJ
Case Rep Neurol; 2022; 14(1):38-43. PubMed ID: 35350291
[TBL] [Abstract][Full Text] [Related]
10. PARP-1 deregulation in multiple sclerosis.
Meira M; Sievers C; Hoffmann F; Bodmer H; Derfuss T; Kuhle J; Haghikia A; Kappos L; Lindberg RL
Mult Scler J Exp Transl Clin; 2019; 5(4):2055217319894604. PubMed ID: 31897308
[TBL] [Abstract][Full Text] [Related]
11. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Oshima Y; Tanimoto T; Yuji K; Tojo A
Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084
[TBL] [Abstract][Full Text] [Related]
12. Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk.
Marignier R; Durand-Dubief F; du Pasquier R; Vukusic S
Ann Neurol; 2016 Nov; 80(5):791. PubMed ID: 27554031
[No Abstract] [Full Text] [Related]
13. Immune checkpoint inhibitors: A potential bright spot in the treatment of progressive multifocal leukoencephalopathy in multiple sclerosis.
Motte J; Gold R
Mult Scler; 2023 Feb; 29(2):306-307. PubMed ID: 36451582
[No Abstract] [Full Text] [Related]
14. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
15. Author response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
Berger JR; Cree BA; Greenberg B; Hemmer B; Ward BJ; Dong VM; Merschhemke M
Neurology; 2019 Jan; 92(3):151. PubMed ID: 30643034
[No Abstract] [Full Text] [Related]
16. Reader response: Progressive multifocal leukoencephalopathy after fingolimod treatment.
Lalive PH; Roth S; Du Pasquier R
Neurology; 2019 Jan; 92(3):151. PubMed ID: 30643033
[No Abstract] [Full Text] [Related]
17. Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy.
Takahashi K
J Clin Neurosci; 2019 May; 63():91-94. PubMed ID: 30772201
[TBL] [Abstract][Full Text] [Related]
18. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.
Zhang Y; Wright C; Flores A
J Med Case Rep; 2018 Jul; 12(1):187. PubMed ID: 29960601
[TBL] [Abstract][Full Text] [Related]
19. Cortical hypointensity in T2-weighted gradient-echo sequences in patients with progressive multifocal leukoencephalopathy.
López Sala P; Alberdi Aldasoro N; Zelaya Huerta MV; Bacaicoa Saralegui MC; Cabada Giadás T
Radiologia (Engl Ed); 2020; 62(1):59-66. PubMed ID: 31375267
[TBL] [Abstract][Full Text] [Related]
20. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
Puig-Casadevall M; Álvarez-Bravo G; Varela AQ; Robles-Cedeño R; Sànchez Cirera L; Miguela A; Laguillo G; Montalban X; Hauser SL; Ramió-Torrentà L
Eur J Neurol; 2023 Oct; 30(10):3357-3361. PubMed ID: 37485841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
